Brief: Pliant Therapeutics Says Pln-101095 Generally Well Tolerated; Most Common Trae Was Rash, One Grade 3 Trae Observed
18/04/2026 18:33
April 18 (Reuters) - Pliant Therapeutics Inc PLRX.O: PLIANT THERAPEUTICS ANNOUNCES PRESENTATION OF UPDATED DATA FROM THE PHASE 1 TRIAL OF PLN-101095 IN PATIENTS WITH ICI-REFRACTORY SOLID TUMORS AT THE 2026 AACR ANNUAL MEETING PLIANT THERAPEUTICS INC - CONFIRMED RESPONDERS SHOW 89% AVERAGE MAXIMUM TUMOR REDUCTION, 19 MONTHS MEDIAN TIME ON TREATMENT PLIANT THERAPEUTICS INC - PLN-101095 GENERALLY WELL TOLERATED; MOST COMMON TRAE WAS RASH, ONE GRADE 3 TRAE OBSERVED Source text: ID:nGNXb3M3RN Further company coverage: PLRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pliant Therapeutics
See all newsPliant Therapeutics Q1 net loss narrows on lower expenses
Brief: Pliant Therapeutics Says Pln-101095 Generally Well Tolerated; Most Common Trae Was Rash, One Grade 3 Trae Observed
Brief: Pliant Therapeutics Announces Upcoming Presentation Of Phase 1 Clinical Trial Of PLN-101095 In Patients With Solid Tumors At The 2026 Aacr Annual Meeting
Pliant Therapeutics Q4 net loss narrows on lower costs
Brief: Pliant Therapeutics Q4 Net Income USD -23.577 Million